Bain Capital put $300 million into Beeline Medicines at launch, licensing five autoimmune programs from Bristol Myers Squibb to build its next specialty pharma bet. No valuation, no per-share price: it’s a brand-new private company, so what matters is what that $300 million is supposed to get.
The Bain playbook has a recent precedent. Bain built SpringWorks Therapeutics on the same spin-out model, then watched it sell to Merck KGaA for $3.9 billion in April 2025. Beeline’s CEO Saqib Islam and president Badreddin Edris both ran SpringWorks through that exit. They’re running the same play in a new indication.
So what does $300 million actually buy? The lead asset is afimetoran, an oral TLR7/TLR8 inhibitor in phase 2 for cutaneous lupus erythematosus. The phase 2 is expected to wrap by year-end, with a pivotal lupus trial launching after that. Behind it: BMS-986326, an IL-2-CD25 fusion protein in phase 1b for atopic dermatitis and lupus, and lomedeucitinib, a phase 2 TYK2 inhibitor for plaque psoriasis. Two preclinical biologics targeting IL-10 and IL-18 round out the five licensed programs.
Lupus alone affects roughly five million people, giving afimetoran a patient population that can support a commercial-stage company.
The pivotal trial question will define Beeline’s eventual exit multiple. Bain’s done this before; the afimetoran phase 2 read will tell investors whether the sequel justifies the $300 million ticket. Data is due by year-end.
Diana Kowalski